(VIANEWS) – AMSC (AMSC.OL), NAVAMEDIC (NAVA.OL), SKUE SPAREBANK (SKUE.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, operates as a ship owning and lease finance company in the United States. The company purchases and bareboat charters out vessels to operators and end users. It operates a fleet of nine product tankers, one shuttle tanker, and one subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was founded in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr2.05.
PE Ratio
AMSC has a trailing twelve months price to earnings ratio of 19.8. Meaning, the purchaser of the share is investing kr19.8 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
Yearly Top and Bottom Value
AMSC’s stock is valued at kr40.60 at 07:20 EST, way below its 52-week high of kr48.80 and way higher than its 52-week low of kr34.15.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 75.8% and 46.8%, respectively.
Moving Average
AMSC’s value is above its 50-day moving average of kr39.16 and below its 200-day moving average of kr41.54.
Sales Growth
AMSC’s sales growth is 1367.3% for the ongoing quarter and 1395% for the next.
More news about AMSC.
2. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.2.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.58. Meaning, the purchaser of the share is investing kr32.58 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Moving Average
NAVAMEDIC’s worth is way higher than its 50-day moving average of kr35.03 and higher than its 200-day moving average of kr36.36.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
More news about NAVAMEDIC.
3. SKUE SPAREBANK (SKUE.OL)
11.9% sales growth and 9.5% return on equity
Skue Sparebank provides various banking products and services for individual and business in Norway. The company offers operating, tax deduction, capital, client, deposit, and group accounts; business, construction, personal, vehicle, and small loans, as well as mortgage, bank guarantee, overdraft, and leasing services; and home and leisure, car and other vehicles, pet, company and employees, agriculture insurance products. It also provides savings and pension products; and online and mobile banking, bank card, and payment services. The company was formerly known as Nes Prestegjelds Sparebank and changed its name to Skue Sparebank in October 2013. Skue Sparebank was founded in 1842 and is based in Geilo, Norway.
Earnings Per Share
As for profitability, SKUE SPAREBANK has a trailing twelve months EPS of kr85.82.
PE Ratio
SKUE SPAREBANK has a trailing twelve months price to earnings ratio of 2.56. Meaning, the purchaser of the share is investing kr2.56 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.5%.
Sales Growth
SKUE SPAREBANK’s sales growth for the next quarter is 11.9%.
Yearly Top and Bottom Value
SKUE SPAREBANK’s stock is valued at kr220.00 at 07:20 EST, way below its 52-week high of kr246.00 and way above its 52-week low of kr198.00.
Volume
Today’s last reported volume for SKUE SPAREBANK is 704 which is 68.01% above its average volume of 419.
More news about SKUE SPAREBANK.
4. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. Bouvet ASA was founded in 1995 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.09.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 18.03. Meaning, the purchaser of the share is investing kr18.03 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
More news about BOUVET.
5. NORBIT (NORBT.OL)
9.7% sales growth and 27.5% return on equity
Norbit ASA provides technology products and solutions. It operates through Oceans, Connectivity, and Product Innovation and Realization segments. The company offers multibeam sonar systems, including integrated bathymetric systems, bathymetry systems, advanced monitoring systems for dredging, construction and renewables, forward looking wide area imaging, advanced imaging systems for obstacle avoidance/MCM, and above water laser products under the NORBIT WINGHEAD, NORBIT WBMS, NORBIT NORdredge, and NORBIT FLS names; customized cable assemblies, electromechanical box builds, and operational solutions; SeaCOP, a sensor integration platform and user interface common operational picture for emergency response; SECurus provides thermal and daylight stabilized camera solutions; SeaView, which offers thermal and daylight, pan, tilt, and zoom for environmental monitoring, and security and general surveillance; and SeaDarQ, a radar processing solution. It also provides sensing solutions for detecting threats at sea plus waterside security above and below the surface; FCL600, an underwater light solution for aquaculture industry; iData, which offers vehicle monitoring, telematics services, and fleet management for asset and vehicle management; and dedicated short-range communication technology for traffic system and vehicle application. In addition, the company offers research and development services, and contract manufacturing to industrial customers; and sells products based on proprietary technology, including special instrumentation n based on radar, radio frequency, and embedded signal processing technology. The company was founded in 1995 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, NORBIT has a trailing twelve months EPS of kr2.9.
PE Ratio
NORBIT has a trailing twelve months price to earnings ratio of 19.1. Meaning, the purchaser of the share is investing kr19.1 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.5%.
Moving Average
NORBIT’s worth is below its 50-day moving average of kr59.54 and way higher than its 200-day moving average of kr45.44.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 5, 2023, the estimated forward annual dividend rate is 0.7 and the estimated forward annual dividend yield is 1.21%.
More news about NORBIT.
6. MEDISTIM (MEDI.OL)
5.8% sales growth and 34.9% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.33.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 33.65. Meaning, the purchaser of the share is investing kr33.65 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 7.44.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr213.00 at 07:20 EST, way below its 52-week high of kr312.50 and way higher than its 52-week low of kr184.80.
More news about MEDISTIM.
